Laru-Zova Meets Pivotal X-Linked Retinitis Pigmentosa Endpoint

Company Beacon Therapeutics Event Type Pivotal Trial Readout Modality AAV Gene Therapy (Subretinal Injection) Asset Laru-Zova (AGTC-501) Target RPGR ORF15 Replacement Disease Area X-Linked Retinitis Pigmentosa Summary Beacon Therapeutics reported that the pivotal VISTA study met its FDA-endorsed Month 12 primary endpoint in 85 males…